CRISPR Therapeutics
CRSP
CRSP
182 hedge funds and large institutions have $1.13B invested in CRISPR Therapeutics in 2019 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 51 increasing their positions, 51 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
1.43% less ownership
Funds ownership: 51.82% → 50.39% (-1.4%)
12% less capital invested
Capital invested by funds: $1.29B → $1.13B (-$158M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Holders
182
Holding in Top 10
5
Calls
$23.9M
Puts
$22.9M
Top Buyers
| 1 | +$37.1M | |
| 2 | +$21.2M | |
| 3 | +$15.8M | |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$14.6M |
| 5 |
AC
Armistice Capital
New York
|
+$10.8M |
Top Sellers
| 1 | -$75.8M | |
| 2 | -$22.2M | |
| 3 | -$12.2M | |
| 4 |
JP Morgan Chase
New York
|
-$5.18M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.17M |